A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Clinical trial NCT00750698 · TERMINATED

Trial details

NCT number: NCT00750698
Sponsor: Syndax Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2008-08-01
Primary completion: 2010-05-01
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.